Abstract
Before releasing a product, manufacturers have to follow a regulatory framework and meet standards, producing reliable evidence that the device presents low levels of risk in use. There is, though, a gap between the needs of the manufacturers to conduct usability testing while managing their costs, and the requirements of authorities for representative evaluation data. A key issue here is the number of users that should complete this evaluation to provide confidence in a product's safety. This paper reviews the US FDA's indication that a sample composed of 15 participants per major group (or a minimum of 25 users) should be enough to identify 90-97% of the usability problems and argues that a more nuanced approach to determining sample size (which would also fit well with the FDA's own concerns) would be beneficial. The paper will show that there is no a priori cohort size that can guarantee a reliable assessment, a point stressed by the FDA in the appendices to its guidance, but that manufacturers can terminate the assessment when appropriate by using a specific approach-illustrated in this paper through a case study-called the 'Grounded Procedure'.
Original language | English |
---|---|
Pages (from-to) | 513-525 |
Number of pages | 13 |
Journal | Expert review of medical devices |
Volume | 11 |
Issue number | 5 |
DOIs | |
Publication status | Published - 1 Jan 2014 |
Externally published | Yes |
Keywords
- evaluation cohort
- five-user assumption
- medical devices
- product safety
- usability testing